Amplia Therapeutics Ltd. has halted recruitment in its phase II Amplicity trial in advanced pancreatic cancer due to three dose-limiting toxicities related to the chemotherapy regimen, modified FOLFIRINOX (mFOLFIRINOX), which is being administered in combination with lead compound narmafotinib (AMP-945), a focal adhesion kinase inhibitor.
German company Tubulis GmbH, which emerged with a $12.3 million series A round and a next-generation antibody-drug conjugate (ADC) platform about six years ago, has commanded up to $5 billion in a buyout offer from Gilead Sciences Inc.
Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Cocrystal, Context, Fore, Eli Lilly, Merck, Ultragenyx, Zeto.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Adagene, Axsome, Boston Scientific, BSM, Ellipsys, Gilead, Incyte, Lupin, Oncotelics, Phil, Shionogi, Takeda, Tanabe, Techforce, Tenpoint, Valencia, Visufarma.
Clinical updates for biopharma and med tech, including data readouts and publications: Adagene, Alto Neuroscience, Astrazeneca, Beam, Immunovant, Lipocine, Neutrolis, Novo Nordisk, Pangia, Puretech, Seaport, Soligenix, Vascarta.
Biopharma and med-tech companies raising money in public or private financings, including: Adagene, Arch Biopartners, Celldex, Entera, Hoth, Inovio, Stairmed.
RSS
